Novartis Inks Second Molecular Glue Deal With Monte Rosa Worth Up to $5.7 Billion
Novartis; Monte Rosa Therapeutics; molecular glue degraders; $5.7 billion deal; drug discovery; immunology; QuEEN platform; autoimmune diseases; upfront payment; royalties; collaboration
Novartis Expands Degrader-Focused Collaboration with Monte Rosa Through Major Molecular Glue Deal
Novartis; Monte Rosa Therapeutics; molecular glue degraders; MRT-6160; VAV1 protein; immune-mediated diseases; drug discovery; collaboration; milestone payments; AI/ML-enabled product engine
aTyr’s Steroid-Sparing Lung Disease Drug Disappoints in Late-Stage Trial
aTyr Pharma; efzofitimod; steroid-sparing; pulmonary sarcoidosis; interstitial lung disease
Lila Sciences Raises $235M to Expand AI Science Factories
Lila Sciences; AI Science Factories; Autonomous Research; Biotechnology; Series A Funding
FDA Targets Misleading Drug Ads, Shifting Strategy Could Make Ads Less Feasible
FDA; Marty Makary; Drug Ads; Regulatory Crackdown
RFK Jr. Names 8 New ACIP Members, Replacing Prior Committee Before Key Vaccine Votes
RFK Jr.; ACIP; CDC; vaccine advisors; COVID-19; measles; Robert F. Kennedy Jr.; vaccine safety; committee shakeup
AstraZeneca Pauses £200M Expansion in UK Amid Pharma Uncertainty
AstraZeneca; UK Pharma; Investment; Cambridge; Expansion Pause
Eli Lilly Pauses UK Biotech Incubator Plans Amid Concerns Over NHS Drug Pricing
Eli Lilly; Gateway Labs; UK biotech incubator; pause; investment; NHS drug spending; life sciences; biotech industry; government funding; pharmaceutical innovation
Eli Lilly Loses Appeal to Overturn $183.7 Million Medicaid Rebate Judgment
Eli Lilly; Medicaid; rebate; court ruling; False Claims Act; drug pricing; whistleblower; 7th Circuit Court of Appeals; fraud; $183.7 million judgment
FibroGen Settles with SEC for $1.25M Over Roxadustat Data Tampering Allegations
FibroGen; SEC; roxadustat; data manipulation; settlement; Kin-Hung Peony Yu; phase 3 clinical trial; anemia drug; cardiovascular safety; FDA